Goldman Sachs’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,610,731
| Closed | -$84.5M | – | 5899 |
|
|
2020
Q3 | $84.5M | Buy |
1,610,731
+677,446
| +73% | +$28M | 0.02% | 658 |
|
|
2020
Q2 | $31.1M | Buy |
933,285
+69,888
| +8% | +$2.23M | 0.01% | 1329 |
|
|
2020
Q1 | $23.5M | Buy |
863,397
+226,916
| +36% | +$6.32M | 0.01% | 1397 |
|
|
2019
Q4 | $12.6M | Buy |
636,481
+197,524
| +45% | +$3.16M | ﹤0.01% | 2263 |
|
|
2019
Q3 | $5.69M | Buy |
438,957
+4,275
| +1% | +$51.6K | ﹤0.01% | 2755 |
|
|
2019
Q2 | $5.41M | Sell |
434,682
-79,323
| -15% | -$1.05M | ﹤0.01% | 2796 |
|
|
2019
Q1 | $7.47M | Buy |
514,005
+211,588
| +70% | +$2.7M | ﹤0.01% | 2662 |
|
|
2018
Q4 | $3.34M | Sell |
302,417
-70,298
| -19% | -$978K | ﹤0.01% | 3201 |
|
|
2018
Q3 | $9.8M | Sell |
372,715
-113,798
| -23% | -$3.08M | ﹤0.01% | 2472 |
|
|
2018
Q2 | $9.95M | Buy |
486,513
+26,660
| +6% | +$572K | ﹤0.01% | 2417 |
|
|
2018
Q1 | $8.35M | Buy |
459,853
+181,273
| +65% | +$3.02M | ﹤0.01% | 2493 |
|
|
2017
Q4 | $3.89M | Sell |
278,580
-261,269
| -48% | -$3.53M | ﹤0.01% | 3247 |
|
|
2017
Q3 | $9.99M | Sell |
539,849
-229,254
| -30% | -$3.83M | ﹤0.01% | 2553 |
|
|
2017
Q2 | $13M | Buy |
769,103
+274,704
| +56% | +$4.18M | ﹤0.01% | 2304 |
|
|
2017
Q1 | $6.6M | Buy |
494,399
+148,092
| +43% | +$2.32M | ﹤0.01% | 2709 |
|
|
2016
Q4 | $5.21M | Buy |
346,307
+39,905
| +13% | +$527K | ﹤0.01% | 3020 |
|
|
2016
Q3 | $3.58M | Buy |
306,402
+216,914
| +242% | +$2.55M | ﹤0.01% | 3337 |
|
|
2016
Q2 | $967K | Sell |
89,488
-21,904
| -20% | -$226K | ﹤0.01% | 4211 |
|
|
2016
Q1 | $1.03M | Sell |
111,392
-544
| -0.5% | -$5.85K | ﹤0.01% | 4053 |
|
|
2015
Q4 | $1.66M | Sell |
111,936
-71,366
| -39% | -$1.19M | ﹤0.01% | 3801 |
|
|
2015
Q3 | $3.01M | Sell |
183,302
-58,215
| -24% | -$1.19M | ﹤0.01% | 3377 |
|
|
2015
Q2 | $5.51M | Buy |
241,517
+3,184
| +1% | +$63.4K | ﹤0.01% | 2870 |
|
|
2015
Q1 | $3.62M | Buy |
238,333
+16,021
| +7% | +$208K | ﹤0.01% | 3201 |
|
|
2014
Q4 | $2.68M | Sell |
222,312
-85,860
| -28% | -$981K | ﹤0.01% | 3553 |
|
|
2014
Q3 | $3.49M | Sell |
308,172
-14,727
| -5% | -$168K | ﹤0.01% | 3373 |
|
|
2014
Q2 | $3.9M | Buy |
322,899
+94,972
| +42% | +$1.12M | ﹤0.01% | 3304 |
|
|
2014
Q1 | $2.65M | Buy |
227,927
+5,135
| +2% | +$87K | ﹤0.01% | 3696 |
|
|
2013
Q4 | $3.94M | Sell |
222,792
-266,162
| -54% | -$4.47M | ﹤0.01% | 3351 |
|
|
2013
Q3 | $7.04M | Buy |
488,954
+43,246
| +10% | +$662K | ﹤0.01% | 2591 |
|
|
2013
Q2 | $6.71M | Buy |
+445,708
| New | +$5.88M | ﹤0.01% | 2442 |
|
Goldman Sachs's MNTA Position: Q4 2020 in Review
Goldman Sachs sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 1,610,731 shares — an estimated $84.5M sold.
Goldman Sachs first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $84.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Goldman Sachs reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 1,610,731 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $84.5M.
- Goldman Sachs first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- Goldman Sachs's Momenta Pharmaceuticals, Inc. position peaked at $84.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.